Managing IP hosted the inaugural MIP Life Sciences Forum 2016 in New York on September 14.Over the past year IP owners in the life sciences sector have been facing uniqueopportunities and challenges when protecting their patents. Rapid developments inthe landscape of drug discovery, research and pending proposals for reform inCongress means that your strategies to protect your IP may need rethinking.As such, the Forum tracked legislative developments within the life sciences sector, examined the potential impact and forecasted one, five and 10-year horizon for changes. In addition, the Forum addressed:
Senior IP and general counsel from leading pharmaceutical and life sciences organisations shared their experiences of managing IP matters and engaged in lively debate on all the pertinent topics within life sciences from varied perspectives. EVENT FEEDBACK"Well qualified speakers, latest perspectives, great forum in an intimate environment""Highly practical information, insights and analysis!"The conference was very high quality and the speakers were very knowledgeable. I like that they pointed out practice tips and tried to predict where the law might go.""The topics were ideal for the issues facing the protection of biotech IP""Thank you for the invitation to attend this. It really was a first-rate event."Key takeaways from the event will be made available shortly and you can view photos from the event here.To receive advance notice for the next year's event, email email@example.com
May / June 2019
From trademarks to trade secrets: in-house tips on brand protection in China
Despite the well-known struggles in protecting trademarks and trade secrets in China, there are some tried-and-tested strategies to employ, as Karry Lai and Ellie Mertens hear from in-house counsel at a range of domestic and international companies
The material on this site is for financial institutions, professional investors
and their professional advisers. It is for information only. Please read our
Terms and Conditions
before using the site. All material subject to strictly enforced copyright laws.
© 2019 Euromoney Institutional Investor PLC. For help please
see our FAQ.
Switching to MIP International